m⁶A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia

References

• Hu L, Gao Y, Shi Z, et al. DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients. Ann Transl Med. 2019;7(23):737.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Awan FT. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematol Oncol. 2010;28:3–20.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Jaramillo S, Müller-Tidow C. What’s new in consolidation therapy in AML? Semin Hematol. 2019;56:96–101.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577–590.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid Leukemia. N Engl J Med. 2016;374:2209–2221.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.
   PubMed Web of Science ®Google Scholar
• Ianniello Z, Paiardini A, Fatica A. N(6)-methyladenosine (m(6)A): a promising new molecular target in acute myeloid Leukemia. Front Oncol. 2019;9:251.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2008;66:181–193.
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu X, Song L, et al. Melatonin restores the pluripotency of long-term-cultured embryonic stem cells through melatonin receptor-dependent m6A RNA regulation. J Pineal Res. 2020;69(2):e12669.
   PubMed Web of Science ®Google Scholar
• Mill CP, Fiskus W, DiNardo CD, et al. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019;134(1):59–73.
   PubMed Web of Science ®Google Scholar
• Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019;32:134–144.
   PubMed Web of Science ®Google Scholar
• Monma F, Nishii K, Shiga J, et al. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients. Leuk Res. 2007;31:471–476.
   PubMed Web of Science ®Google Scholar
• Mohamed AM, Balsat M, Koering C, et al. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML. Leuk Res. 2017;56:21–28.
   PubMed Web of Science ®Google Scholar
• Spencer DH, Russler-Germain DA, Ketkar S, et al. CpG Island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell. 2017;168:801–816.e813.
   PubMed Web of Science ®Google Scholar
• Vu LP, Pickering BF, Cheng Y, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369–1376.
   PubMed Web of Science ®Google Scholar
• Batista PJ. The RNA modification N(6)-methyladenosine and its implications in human disease. Genomics Proteomics Bioinformatics. 2017;15:154–163.
   PubMed Web of Science ®Google Scholar
• Qing Y, Dong L, Gao L, et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m(6)A/PFKP/LDHB axis. Mol Cell. 2021;81:922–939.e929.
   PubMed Web of Science ®Google Scholar
• Paris J, Morgan M, Campos J, et al. Targeting the RNA m(6)A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid Leukemia. Cell Stem Cell. 2019;25:137–148.e136.
   PubMed Web of Science ®Google Scholar
• Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78:1019–1033.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–550.
   PubMed Web of Science ®Google Scholar
• Malta TM, Sokolov A, Gentles AJ, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173:338–354.e315.
   PubMed Web of Science ®Google Scholar
• Guo W, Tan F, Huai Q, et al. Comprehensive analysis of PD-L1 expression. Front Immunol. 2021;12:669750.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wu Q, Li B, et al. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19:53.
   PubMed Web of Science ®Google Scholar
• Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270–274.
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
   PubMed Web of Science ®Google Scholar
• de Hoon MJ, Imoto S, Nolan J, et al. Open source clustering software. Bioinformatics. 2004;20:1453–1454.
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747–1756.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572–1573.
   PubMed Web of Science ®Google Scholar
• Symsack A, Gaunaurd I, Thaper A, et al. Usability assessment of the rehabilitation lower-limb orthopedic assistive device by service members and veterans with lower limb loss. Mil Med. 2021;186:379–386.
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
   PubMed Web of Science ®Google Scholar
• Zeng L, Fan X, Wang X, et al. Bioinformatics analysis based on multiple databases identifies hub genes associated with hepatocellular Carcinoma. Curr Genomics. 2019;20:349–361.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284–287.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262.
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li ZY, Zhou GQ, et al. An immune-related gene prognostic index for head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27:330–341.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–1377.
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606.
   PubMed Web of Science ®Google Scholar
• Liu N, Pan T. N6-methyladenosine–encoded epitranscriptomics. Nat Struct Mol Biol. 2016;23:98–102.
   PubMed Web of Science ®Google Scholar
• Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid Leukemia as a N(6)-methyladenosine RNA demethylase. Cancer Cell. 2017;31:127–141.
   PubMed Web of Science ®Google Scholar
• Bansal H, Yihua Q, Iyer SP, et al. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia. 2014;28:1171–1174.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhao BS, Zhou A, et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31:591–606.e596.
   PubMed Web of Science ®Google Scholar
• Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016;113:E2047–2056.
   PubMed Web of Science ®Google Scholar
• Lin S, Choe J, Du P, et al. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335–345.
   PubMed Web of Science ®Google Scholar
• Du A, Wu X, Gao Y, et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in acute myeloid Leukemia. Front Immunol. 2021;12:789914.
   PubMed Web of Science ®Google Scholar
• Han S, Qi J, Fang K, et al. Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia. Cancer Med. 2022;11:1413–1426.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz AM, Sun Y, Hellmich C, et al. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment. Blood. 2019;133:446–456.
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10:96–103.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330.
   PubMed Web of Science ®Google Scholar
• Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-t-cell-inflamed tumor microenvironment. Semin Oncol. 2015;42:663–671.
   PubMed Web of Science ®Google Scholar
• Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65:529–543.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19:46.
   PubMed Web of Science ®Google Scholar
• Weng H, Huang H, Wu H, et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes Leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018;22:191–205.e199.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng JN, Wang EH, et al. The m6A reader protein YTHDC2 is a potential biomarker and associated with immune infiltration in head and neck squamous cell carcinoma. PeerJ. 2020;8:e10385.
   PubMed Web of Science ®Google Scholar
• Gong PJ, Shao YC, Yang Y, et al. Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer. Front Oncol. 2020;10:578963.
   PubMed Web of Science ®Google Scholar
• Raffel GD, Mercher T, Shigematsu H, et al. Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci U S A. 2007;104:6001–6006.
   PubMed Web of Science ®Google Scholar
• Li HB, Tong J, Zhu S, et al. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548:338–342.
   PubMed Web of Science ®Google Scholar
• Tong J, Cao G, Zhang T, et al. m(6)A mRNA methylation sustains Treg suppressive functions. Cell Res. 2018;28:253–256.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550–1558.
   PubMed Web of Science ®Google Scholar